NEW DELHI: COVAXIN will be tested as a vaccine for COVID-19 in the United States. Making the announcement, Bharat Biotech said Ocugen had announced that the US Food and Drug Administration (FDA) had approved the company’s Investigational New Drug (IND) application to evaluate a COVID-19 vaccine candidate.
Ocugen is jointly developing COVAXIN for COVID-19 in the US and Canada.
Drs. Shankar Musunuri, President, CEO and Founder Or co-founder, Ocugen, said, “We are very excited to be able to continue our COVAXIN clinical program, which we hope will bring us closer to providing another COVID-19 vaccine.”
We strongly believe that more immunizations are needed to stem the tide of the epidemic, so we are pleased that we have been able to continue developing the immunization target, he said.
COVAXIN is a traditional Indian vaccine for COVID-19, developed by Bharat Biotech and developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
It is developed by Whole-Virion Inactivated Vero Cell-derived platform technology.
They are unlikely to revert and cause pathological effects, as inactivated vaccines do not replicate.
According to Bharat Biotech, they contain dead Viruses, which can’t infect humans, but can still command the immune system to develop an immune response against an infection.
More than 2 crore teens in the 15-18 age group are now vaccinated against coronavirus, said Health and Family Welfare Minister Mansukh Mandaviya.
According to the government website CoWIN, 7,38,74,876 vaccines have been completed in this group so far.